Great Point Partners’s Dianthus Therapeutics DNTH Stock Holding History

Great Point Partners’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-350,000	Closed	-$14.4M	–	43
2025 Q4	$14.4M	Buy	350,000 +84,197	+32%	+$3.26M	4.68%	9
2025 Q3	$10.5M	Buy	+265,803	New	+$6.79M	4.31%	9
2025 Q2	–	Sell	-275,000	Closed	-$4.99M	–	30
2025 Q1	$4.99M	Hold	275,000	–	–	2.64%	16
2024 Q4	$6M	Hold	275,000	–	–	2.83%	16
2024 Q3	$7.53M	Sell	275,000 -482,929	-64%	-$13.5M	2.22%	20
2024 Q2	$19.6M	Buy	757,929 +132,929	+21%	+$3.2M	3.76%	10
2024 Q1	$18.8M	Buy	+625,000	New	+$13.6M	2.92%	16
2022 Q4	–	Sell	-63,693	Closed	-$1.44M	–	44
2022 Q3	$1.44M	Sell	63,693 -9,432	-13%	-$258K	0.35%	36
2022 Q2	$1.4M	Hold	73,125	–	–	0.34%	34
2022 Q1	$3.39M	Hold	73,125	–	–	0.82%	26
2021 Q4	$5.18M	Hold	73,125	–	–	1.15%	29
2021 Q3	$8.52M	Buy	73,125 +3,681	+5%	+$429K	1.98%	24
2021 Q2	$10.9M	Buy	+69,444	New	+$12.8M	2.28%	21

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Great Point Partners's DNTH Position: Q1 2026 in Review

Great Point Partners sold out of Dianthus Therapeutics (DNTH) in Q1 2026, closing a stake of 350,000 shares — an estimated $14.4M sold.

Great Point Partners first reported a position in DNTH in Q2 2021 and held it in 13 quarters. The position peaked at $19.6M in Q2 2024. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

Great Point Partners reported no remaining Dianthus Therapeutics position as of Q1 2026 after selling out during the quarter.
Great Point Partners sold 350,000 Dianthus Therapeutics shares in Q1 2026, an estimated $14.4M.
Great Point Partners first reported a position in Dianthus Therapeutics in Q2 2021 and held it in 13 quarters.
Great Point Partners's Dianthus Therapeutics position peaked at $19.6M in Q2 2024.
241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Great Point Partners's 13F filing for Q1 2026, filed 15 May 2026.